[1] Jemal AS,Rebecca Xu JW,Elizabeth.Cancer Statistics[J].CA CANCER J CLIN,2010,60(5):23. [2] 刘振伟,项永兵,张薇,等.上海市区1973~1999年前列腺癌发病趋势分析[J].中国卫生统计,2003,20(6):335-337. [3] 吴海涵,翁志梁,李湘斌,等.5α-还原酶抑制剂治疗对前列腺增生患者血清性激素水平的影响[J].中国男科学杂志,2007,21(3):44-46. [4] Russell DW,Wilson JD.Steroid 5 alpha-reductase: two genes/two enzymes[J].Annu Rev Biochem,1994,63(1):25-61. [5] 刘本,常忆凌,陈科力.5α还原酶作为天然药物筛选靶的研究进展[J].药物生物技术,2006,13(6):468-470. [6] 王梦芝.良性前列腺增生症的药物治疗进展[J].当代医学,2010,16(14):24-26. [7] 孙华君,刘少明.5α还原酶抑制剂临床研究进展[J].世界临床药物,2006,27(2):95-101. [8] Zu-Yue Sun WZ,Jie Feng ZT.A convenient and rapid method to study enzymatic kinetics of steroid 5a-reductase inhibitors[J].Indian Journal of Pharmacology,1998,30(4):257-262. [9] Schafhauser W EA,Kiihn R KH,Culig Z.Effect of epristeride and bicalutamide on human prostate cancer PCEW on the nude mouse mode[J].J Eur Urol,1998,34(3):252-253. [10] Sun ZY,Feng J,Qi XD,et al.Reversible long-term toxicity of epristeride in beagle dogs[J].Toxicol Appl Pharmacol,1999,154(2):145-52. [11] Wu SF,Sun HZ,Qi XD,et al.Effect of epristeride on the expression of IGF-1 and TGF-beta receptors in androgen-induced castrated rat prostate[J].Exp Biol Med (Maywood),2001,226(10):954-60. [12] Wu SF,Sun HZ,Tu ZH,et al.Inhibition of cultured rat prostatic epithelial cell growth by epristeride in vitro[J].Acta Pharmacol Sin,2001,22(3):257-63. [13] John C.Lamb JTI,Mark A.Levy RKJ.Response of rat and human prostatic cancers to the novel 5-reductase inhibitor[J].SK&F 105657.Prostate,1992,21(1):15-34. |